Oncologie

Cefepime (CEP) versus Imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia

37th ICAAC – Toronto, Ontario, Canada – September 28-October 1, 1997 Biron P, Fuhrmann C, Kheder R, Viens P, Lefebvre D, Beal J, Thyss A, Viot M and CEMIC, Soler P, Rollin C, Gres J-J.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Risk Factors TFR CP-CML
Success stories - Oncologie - Facultatif

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients

Long-Term TKI Treatment Patterns
Success stories - Oncologie - Facultatif

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life”

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development